Indium-111-capromab pendetide scans: an important test relevant to clinical decision making
- 1 March 2001
- Vol. 57 (3) , 399-401
- https://doi.org/10.1016/s0090-4295(00)01084-0
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancerUrology, 1999
- IN-111 CAPROMAB PENDETIDE MAB SCAN PREDICTS RESPONSE TO RADIOTHERAPY TO THE PROSTATE FOSSA IN MEN WITH TUMOR RECURRENCE FOLLOWING RADICAL PROSTATECTOMYJournal of Urology, 1999
- Comparison of clinical staging algorithms and111Indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patientsCancer, 1999
- Indium-111 Capromab Pendetide (ProstaScint) Imaging to Detect Recurrent and Metastatic Prostate CancerClinical Nuclear Medicine, 1998
- LONG-TERM RESULTS OF RADIATION THERAPY FOR PROSTATE CANCER RECURRENCE FOLLOWING RADICAL PROSTATECTOMYJournal of Urology, 1998
- Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.Journal of Clinical Oncology, 1998
- Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomyUrology, 1996